Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin

ConclusionBaseline IL-6 is an important prognostic factor in patients with MBC treated with eribulin. Our results show that high IL-6 is associated with higher levels of MDSCs which suppress anti-tumor immunity, such as CD8+ cells. It appears that eribulin is not particularly effective in patients with high IL-6 due to a poor tumor immune microenvironment.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research